Details of Disease

General Information of Disease (ID: DISEM33Q)

• Disease Name: Infectious disease
• Synonyms: disease by infectious agent; clinical infection; infectious diseases and manifestations; communicable disease; infectious disorder; infectious; infection; transmissible disease; infectious disease
• Disease Class: 1A00-CA43: Postoperative inflammation
• Definition: A disorder directly resulting from the presence and activity of a microbial, viral, or parasitic agent in humans. It can be transmitted by direct or indirect contact.|Replaces 'infection' in disease hierarchy. OBI imported term infection is moved to pathologic process. This class is a container class for infectious diseases, not the process of infection itself.
• Disease Hierarchy:
  DISH7H5I: Human disease
  DISEM33Q: Infectious disease
• ICD Code:
  ICD-11: ICD-11: 1A00-CA43.1
  ICD-10: ICD-10: A00-B99
• Disease Identifiers:
  MONDO ID: MONDO_0005550
  MESH ID: D003141
  UMLS CUI: C0009450
  MedGen ID: 1057
  SNOMED CT ID: 189822004

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 6 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Dextranomer	DMWOP6K	Approved	NA	[1]
GMDP	DML8PNK	Approved	Small molecular drug	[1]
Hydrogen peroxide	DM1NG5W	Approved	Small molecular drug	[2]
KI-0401	DMDEDO0	Approved	NA	[1]
Polyoxidonium	DMJAOT1	Approved	NA	[1]
Rifamycin	DMEH3O7	Approved	Small molecular drug	[3]

This Disease is Treated as An Indication in 18 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
DPT/Hib vaccine	DMELL4B	Phase 3	NA	[4]
E-101	DMM1YC4	Phase 3	Small molecular drug	[5]
Fovepta	DMGMIWX	Phase 3	NA	[6]
NVC-422	DMDI8LV	Phase 2/3	NA	[7]
RP101	DMNIYSZ	Phase 2/3	Small molecular drug	[8]
INCB9471	DMMWC6F	Phase 2a	Small molecular drug	[9]
Brilacidin	DMXI9BP	Phase 2	Small molecular drug	[10]
INTERCEPT	DM3PBMR	Phase 2	NA	[11]
KB001A	DMTMCPZ	Phase 2	Antibody	[12]
RG7745	DMK5PYS	Phase 2	Antibody	[13]
Sitamaquine	DMY3JWO	Phase 2	Small molecular drug	[14]
Ty800	DMKFW7X	Phase 2	NA	[15]
Interferon alpha 5	DMMZSIB	Phase 1/2	NA	[16]
PUR003	DMAB7GS	Phase 1/2	Small molecular drug	[17]
Hookworm vaccine	DMXO6BR	Phase 1	NA	[18]
MK-6406	DMMR6SK	Phase 1	NA	[19]
mRNA MRK-1777	DMICB9P	Phase 1	NA	[20]
S. mutans Replacement Therapy	DMWZDB0	Phase 1	NA	[21]

This Disease is Treated as An Indication in 84 Patented Agent(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
1,2,4-oxadiazole derivative 1	DMESOA8	Patented	Small molecule immunotherapy	[22]
1,2,4-oxadiazole derivative 2	DMA42SB	Patented	Small molecule immunotherapy	[22]
1,2,4-oxadiazole derivative 4	DMT6EDP	Patented	Small molecule immunotherapy	[22]
1,2,4-oxadiazole derivative 5	DM683R7	Patented	Small molecule immunotherapy	[22]
1,2,4-oxadiazole derivative 6	DMFYKBJ	Patented	Small molecule immunotherapy	[22]
1,2,4-oxadiazole derivative 7	DMBT4RJ	Patented	Small molecule immunotherapy	[22]
1,3,4-oxadiazole derivative 1	DMJMCNP	Patented	Small molecule immunotherapy	[22]
1,3,4-oxadiazole derivative 2	DMH26EO	Patented	Small molecule immunotherapy	[22]
1,3,4-oxadiazole derivative 3	DMSR0X6	Patented	Small molecule immunotherapy	[22]
1,3,4-oxadiazole derivative 4	DM4GR2C	Patented	Small molecule immunotherapy	[22]
1,3,4-oxadiazole derivative 5	DMI5VZN	Patented	Small molecule immunotherapy	[22]
1,3,4-oxadiazole derivative 6	DMIEZ6L	Patented	Small molecule immunotherapy	[22]
1,3,4-thiadiazole derivative 1	DMAB8QF	Patented	Small molecule immunotherapy	[22]
1,3,4-thiadiazole derivative 2	DMXIG07	Patented	Small molecule immunotherapy	[22]
1,3-dihydroxy phenyl derivative 1	DMUS7O3	Patented	Small molecule immunotherapy	[22]
1,3-dihydroxy phenyl derivative 2	DM63NX5	Patented	Small molecule immunotherapy	[22]
3-substituted-1,2,4-oxadiazole derivative 1	DMWCT04	Patented	Small molecule immunotherapy	[22]
3-substituted-1,2,4-oxadiazole derivative 2	DMB3806	Patented	Small molecule immunotherapy	[22]
Aromatic acetylene derivative 1	DMGR6X1	Patented	Small molecule immunotherapy	[22]
Aromatic ethylene derivative 1	DMSRKON	Patented	Small molecule immunotherapy	[22]
Benzyl phenyl ether derivative 1	DM6PTOX	Patented	Small molecule immunotherapy	[22]
Benzyl phenyl ether derivative 2	DMMS4EI	Patented	Small molecule immunotherapy	[22]
Biaryl compound 1	DMHEAJQ	Patented	Small molecule immunotherapy	[22]
Biaryl compound 2	DMS8VYE	Patented	Small molecule immunotherapy	[22]
Bromo benzyl ether derivative 1	DMMXQJU	Patented	Small molecule immunotherapy	[22]
Bromo benzyl ether derivative 2	DMVBAUC	Patented	Small molecule immunotherapy	[22]
Cyclic compound 1	DMSVMUT	Patented	Small molecule immunotherapy	[22]
Cyclic compound 2	DMGRBAJ	Patented	Small molecule immunotherapy	[22]
Cyclic compound 3	DMVOEN7	Patented	Small molecule immunotherapy	[22]
Cyclic peptidomimetic derivative 1	DMV2UQ5	Patented	Small molecule immunotherapy	[22]
Cyclic peptidomimetic derivative 2	DMWH3FP	Patented	Small molecule immunotherapy	[22]
Cyclic peptidomimetic derivative 3	DMI7KG4	Patented	Small molecule immunotherapy	[22]
Macrocycle derivative 1	DMN7I9C	Patented	Small molecule immunotherapy	[22]
Macrocycle derivative 2	DM5OEQZ	Patented	Small molecule immunotherapy	[22]
Macrocycle derivative 3	DMYGFTI	Patented	Small molecule immunotherapy	[22]
Macrocycle derivative 4	DMOQBN4	Patented	Small molecule immunotherapy	[22]
Macrocycle derivative 5	DMK3UJY	Patented	Small molecule immunotherapy	[22]
Macrocycle derivative 6	DMQ84KW	Patented	Small molecule immunotherapy	[22]
Macrocycle derivative 7	DMP2JF0	Patented	Small molecule immunotherapy	[22]
Macrocycle derivative 8	DMOMTBE	Patented	Small molecule immunotherapy	[22]
Macrocycle derivative 9	DMARU0E	Patented	Small molecule immunotherapy	[22]
Macrocyclic peptide analog 1	DMS65IT	Patented	Small molecule immunotherapy	[22]
Macrocyclic peptide analog 2	DMOGLBZ	Patented	Small molecule immunotherapy	[22]
Macrocyclic peptide analog 3	DMV172W	Patented	Small molecule immunotherapy	[22]
N-phenyl-pyridine-2-carboxamide derivative 1	DMMDYAV	Patented	Small molecule immunotherapy	[22]
N-phenyl-pyridine-2-carboxamide derivative 2	DM6OG2Y	Patented	Small molecule immunotherapy	[22]
Peptide analog 1	DMF3LIX	Patented	Peptide	[22]
Peptide analog 2	DMYFUM6	Patented	Peptide	[22]
Peptide analog 3	DMYMJV3	Patented	Peptide	[22]
Peptide analog 4	DM5KEVG	Patented	Peptide	[22]
Peptide analog 5	DM8B13I	Patented	Peptide	[22]
Peptide analog 6	DM68M0G	Patented	Peptide	[22]
Phenylate derivative 1	DMEO9QB	Patented	Small molecule immunotherapy	[22]
Phenylate derivative 2	DMG0ZSY	Patented	Small molecule immunotherapy	[22]
PMID30107136-Compound-Example1	DMY37VQ	Patented	Small molecule immunotherapy	[22]
PMID30107136-Compound-Example11	DMD65GU	Patented	Small molecule immunotherapy	[22]
PMID30107136-Compound-Example12	DMN2K10	Patented	Small molecule immunotherapy	[22]
PMID30107136-Compound-Example13	DM4CN9K	Patented	Small molecule immunotherapy	[22]
PMID30107136-Compound-Example14	DMAUFS7	Patented	Small molecule immunotherapy	[22]
PMID30107136-Compound-Example15	DMYHQ0S	Patented	Small molecule immunotherapy	[22]
PMID30107136-Compound-Example16	DM6EKIV	Patented	Small molecule immunotherapy	[22]
PMID30107136-Compound-Example2	DM9HMB4	Patented	Small molecule immunotherapy	[22]
PMID30107136-Compound-Example3	DMDCN43	Patented	Small molecule immunotherapy	[22]
PMID30107136-Compound-Example4	DMRKLTE	Patented	Small molecule immunotherapy	[22]
PMID30107136-Compound-Example41	DMQPIK4	Patented	Small molecule immunotherapy	[22]
PMID30107136-Compound-Example42	DM95FIN	Patented	Small molecule immunotherapy	[22]
PMID30107136-Compound-Example43	DMJSH0F	Patented	Small molecule immunotherapy	[22]
PMID30107136-Compound-Example44	DM8KAIY	Patented	Small molecule immunotherapy	[22]
PMID30107136-Compound-Example45	DMC075A	Patented	Small molecule immunotherapy	[22]
PMID30107136-Compound-Example46	DMYFSAD	Patented	Small molecule immunotherapy	[22]
PMID30107136-Compound-Example47	DM1TCBQ	Patented	Small molecule immunotherapy	[22]
PMID30107136-Compound-Example48	DMH57FG	Patented	Small molecule immunotherapy	[22]
PMID30107136-Compound-Example49	DM4D1WK	Patented	Small molecule immunotherapy	[22]
PMID30107136-Compound-Example50	DMV15GM	Patented	Small molecule immunotherapy	[22]
PMID30107136-Compound-Example51	DM08CBJ	Patented	Small molecule immunotherapy	[22]
PMID30107136-Compound-Example52	DMJ1C0A	Patented	Small molecule immunotherapy	[22]
PMID30107136-Compound-Example53	DM39FDV	Patented	Small molecule immunotherapy	[22]
PMID30107136-Compound-Example54	DM9DL1E	Patented	Small molecule immunotherapy	[22]
PMID30107136-Compound-Example57	DMZXC0D	Patented	Small molecule immunotherapy	[22]
PMID30107136-Compound-Example58	DM3AY9K	Patented	Small molecule immunotherapy	[22]
PMID30107136-Compound-Example59	DM6XWL9	Patented	Small molecule immunotherapy	[22]
PMID30107136-Compound-Example60	DMUZ85A	Patented	Small molecule immunotherapy	[22]
PMID30107136-Compound-Example7	DMS42KH	Patented	Small molecule immunotherapy	[22]
PMID30107136-Compound-Example8	DMBIK28	Patented	Small molecule immunotherapy	[22]

This Disease is Treated as An Indication in 3 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
99mTc-ciprofloxacin	DMSGY5M	Discontinued in Phase 2	NA	[23]
AZD-5099	DMWKYV7	Discontinued in Phase 1	NA	[24]
Wetimicin	DMSZJ5H	Discontinued in Phase 1	NA	[25]

This Disease is Treated as An Indication in 1 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Recombinant protein subunit vaccine, Emergent	DMLD0QD	Preclinical	NA	[26]

This Disease is Treated as An Indication in 21 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ACH-2892	DMSAYMA	Investigative	NA	[27]
Antimicrobial LL-37 cathelicidin	DMSK8ZS	Investigative	NA	[27]
ATI-0409	DMW7YYN	Investigative	NA	[27]
CF-238	DMN6GJW	Investigative	NA	[27]
DIMS-9054	DMJGKND	Investigative	NA	[28]
Disarmin	DM4R91S	Investigative	NA	[27]
ElCams	DMHVBTE	Investigative	NA	[27]
IkT-001	DMV5FT2	Investigative	NA	[27]
LTX-100	DM75M62	Investigative	NA	[27]
MBS-101	DM5VI53	Investigative	NA	[27]
MTL-101	DMPKM1M	Investigative	NA	[27]
PB-108	DMI18AP	Investigative	NA	[27]
PM-181108	DMKC2XN	Investigative	NA	[27]
S3	DMKBU93	Investigative	Small molecular drug	[27]
SF-101	DME9QYS	Investigative	Small molecular drug	[27]
SF-105	DM7CSLO	Investigative	NA	[27]
SF-111	DMFSDCL	Investigative	NA	[27]
SMT-15000	DMVU4SD	Investigative	NA	[27]
SND-121	DM6TR41	Investigative	NA	[27]
SYM-008	DMQ33PW	Investigative	NA	[27]
SYM-009	DMJ0ES5	Investigative	NA	[27]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2448).
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4570).
• [4] ClinicalTrials.gov (NCT01986335) Protectivity and Safety of DTP/HB/Hib (Bio Farma) Vaccines in Infants, Batch Consistency, Multi Center Trial. U.S. National Institutes of Health.
• [5] ClinicalTrials.gov (NCT01297959) Efficacy and Safety of E-101 Solution for Preventing Surgical Site Infections After Colorectal Surgery. U.S. National Institutes of Health.
• [6] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037466)
• [7] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027530)
• [8] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020300)
• [9] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023697)
• [10] ClinicalTrials.gov (NCT02324335) Phase 2 Study to Evaluate the Safety & Efficacy of Brilacidin Oral Rinse in Patients With Head and Neck Cancer. U.S. National Institutes of Health.
• [11] ClinicalTrials.gov (NCT02310412) A Controlled, In Vivo, Pilot Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Treated 7-Day Stored Apheresis Platelet Components in 35% Plasma and 65% InterSol and 7-Day Stored Apheresis Platelet Components in 100% Plasma. U.S. National Institutes of Health.
• [12] ClinicalTrials.gov (NCT01695343) Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment. U.S. National Institutes of Health.
• [13] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800038254)
• [14] ClinicalTrials.gov (NCT00381394) A Study Evaluating Sitamaquine Compared With Amphotericin B In The Treatment Of Visceral Leishmaniasis.. U.S. National Institutes of Health.
• [15] ClinicalTrials.gov (NCT00498654) Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects. U.S. National Institutes of Health.
• [16] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4963).
• [17] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030156)
• [18] ClinicalTrials.gov (NCT02126462) Safety and Immunogenicity of Co-Administered Hookworm Vaccine Candidates Na-GST-1 and Na-APR-1 in Gabonese Adults. U.S. National Institutes of Health.
• [19] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031916)
• [20] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [21] Clinical pipeline report, company report or official report of Oragenics.
• [22] A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678.
• [23] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016416)
• [24] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034406)
• [25] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028068)
• [26] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007158)
• [27] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [28] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1759).
• [29] Emerging therapies for the treatment and prevention of otitis media. Expert Opin Emerg Drugs. 2006 May;11(2):251-64.